- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology - - Findings Support Disease-modifying Potential of CT1812 - PURCHASE, N.Y., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker1 analysis from the Phase 2 ‘SHINE’ study in mild-to-moderate Al ...

公司业务与研发 - 公司为临床阶段生物制药公司，致力于中枢神经系统和视网膜相关疾病的小分子疗法研发[84] - 公司已在路易体痴呆症的2期COG1201（SHIMMER）研究中招募130名患者，预计2024年底报告初步结果[92] - 公司不拥有或运营制造设施，依赖第三方进行CT1812的制造等工作[102] 公司财务状况 - 截至2024年9月30日，公司累计亏损1.673亿美元，2024年前三季度净亏损分别为990万美元和2610万美元，2023年前三季度净亏损分别为670万美元和1760万美元[93] - 截至2024年9月30日，公司有现金及现金等价物2200万美元，仍有5360万美元的累计拨款可用[94] - 公司预计未来将继续产生大量费用和净亏损，需要大量额外资金支持运营[99] - 截至2024年9月30日公司现金及现金等价物不足以支撑未来一年运营存在重大疑虑[129] 临床试验成果 - SHINE试验中，安慰剂组参与者在ADAS - Cog 11量表上182天下降约2.70点，CT1812治疗组平均下降1.66点，CT1812使下降速度减缓39%[88] - 血浆p - tau217低于中位数的CT1812治疗参与者在ADAS - Cog 11量表上认知衰退速度减缓95%，MMSE量表上减缓108%[91] 公司融资情况 - 公司通过多种方式融资，包括政府拨款、股票发行等，截至2024年9月30日ATM下还有约3380万美元股票可售，林肯公园协议下还有3480万美元可支取[94][95][97] - 公司自成立以来从NIA获得约1.71亿美元补助金并从股权证券销售等筹集约1.264亿美元净收益[127] - 公司在未产生可观产品销售收入前将通过多种方式融资[134] 公司费用情况 - 2024年第三季度研发费用为1139.2万美元较2023年同期减少27.7万美元[114] - 2024年第三季度行政费用为307.1万美元与2023年同期相比变化不大[118] - 2024年第三季度补助收入为429.3万美元较2023年同期减少339.1万美元[114] - 2024年第三季度净其他收入为452.6万美元较2023年同期减少347万美元[114] - 2024年前九个月研发费用为3352.2万美元较2023年同期增加792.6万美元[123] - 2024年前九个月行政费用为972.1万美元较2023年同期减少21.8万美元[124] - 2024年前九个月补助收入为1651.6万美元较2023年同期减少151.9万美元[124] - 2024年前九个月净其他收入为81.3万美元较2023年同期增加94.2万美元[125] 公司现金流情况 - 2024年前九个月经营活动使用现金2010万美元主要源于净亏损2610万美元[137] - 2023年前九个月经营活动使用现金1060万美元主要源于净亏损1760万美元[138] - 2024年前九个月投资活动使用现金不到10万美元[139] - 2023年前九个月投资活动使用现金10万美元[139] - 2024年前九个月融资活动提供现金1220万美元[140] - 2023年前九个月融资活动提供现金210万美元[140] 公司其他情况 - 新冠疫情对公司业务有不利影响，包括临床试验和融资等方面[103][105] - 截至2024年9月30日公司有66.2万美元的经营租赁义务[141] - 2024年10月公司以8.65%年利率融资40万美元保险费[141]

药物研发成果 - CT1812使血浆p - tau217水平较低的阿尔茨海默病患者认知衰退减缓95%[1][3] - 公司预计2024年底报告CT1812治疗路易体痴呆症的2期研究的主要结果[1][2] - 正在进行早期阿尔茨海默病2期START研究和干性年龄相关性黄斑变性2期MAGNIFY研究的招募[4] - 2期SHIMMER研究参与者的基线特征已在CTAD上公布[4] - 公司将寻求与FDA就关键的3期项目设计达成一致[2] 财务状况 - 截至2024年9月30日现金及现金等价物约2200万美元总补助资金剩余5360万美元[4] - 2024年第三季度研发费用1140万美元较2023年同期下降[5] - 2024年第三季度一般及行政费用310万美元与2023年同期相比无显著变化[6] - 2024年第三季度净亏损990万美元每股基本和稀释后亏损0.25美元[6] - 公司估计资金可支持运营和资本支出至2025年第二季度[4]

- CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - PURCHASE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat ...

- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER’ study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference ...

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc ...

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE’ Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER’ trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will ...

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company's president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024. Ms. Ricciardi also will host one-on-one investor meetings during which she will highligh ...

PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, supports Lewy Body Dementia Awareness Month and the critical need for more attention, research, and treatments for people with dementia with Lewy bodies (DLB). DLB is the second most common form of progressive dementia, affecting approximately 1.4 million people in the U.S., with no approved treatments ...

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company's president and CEO, Lisa Ricciardi will participate in two investor conferences in September. September 2024 Investor Conferences Event: Chardan Capital Markets Leadership Call Date/Time: September 5, 2024, at 11:00am ET Livestream: Individuals interested in attending the l ...